1. Market Overview The oncology sector remains the most dominant area in healthcare, with over 50% of ongoing clinical trials focused on cancer treatment. In 2023, the global oncology market was valued at $222.36 billion and is projected to reach $521.6 billion by 2033, growing at a CAGR of 8.9%…
Introduction For decades, leaders and organizations have relied on the VUCA framework—Volatility, Uncertainty, Complexity, and Ambiguity—to understand and respond to a turbulent world. Originally developed by the U.S. Army after the Cold War (Bennett & Lemoine, 2014), VUCA provided a language for confronting rapidly shifting geopolitical, economic, and technological landscapes….
Overall IPM Performance: Monthly Growth: IPM monthly growth reached 8.4% in January 2025, following a pattern of significant monthly fluctuations throughout the year. MAT Growth: The Moving Annual Total (MAT) growth for January 2025 slightly increased to 7.7%, up from 7.6% in December 2024. Acute vs. Chronic Segment Analysis: Chronic Segment Dominance: The…
The ZS report discusses how people feel about healthcare today and what can be done to improve it. Frustration with Costs: Many people find healthcare too expensive, leading to an inability to afford necessary care. Access Challenges: Doctors are busy. Scheduling appointments is difficult. It often takes a long time…
Introduction Artificial intelligence (AI) is increasingly pivotal in driving innovation and efficiency as the pharmaceutical industry evolves. From drug discovery to patient care, AI applications are reshaping how companies approach challenges and opportunities in healthcare. This article explores the diverse AI applications within pharmaceuticals, highlighting key impact areas, their effects…
The rise of open-source platforms, such as China’s DeepSeek AI, is poised to transform not just the Tech World but all businesses including pharma. With the power of collaboration and open-source artificial intelligence (AI), initiatives like DeepSeek AI can drive the creation of novel therapeutic targets and molecules. This new…
The untold story of Glenmark’s phenomenal success in building a brand, Telma, which has 16 brand extensions and a combined turnover of Rs 1036 crore. Glenmark’s Telma brand, which contains Telmisartan, has become well-known for treating hypertension and heart failure and preventing heart attacks and strokes. The HBR case study…
Competitor Analysis – Indian Pharma Market Jan 2025 This analysis breaks down the competitive landscape by focusing on Competitor Analysis – Indian Pharma Market (Jan 2025) Market Leaders (Strongest Competitors) These companies have the highest market share, strong brand portfolios, and consistent growth. 🏆 A. Abbott (4 brands in the…
Overall Market Performance (IPM)• The Indian Pharmaceutical Market (IPM) recorded a total value of ₹229,260.6 crore, with an overall growth of 7.6% for Dec’24.• Out of 26 regions, 12 states/regions grew faster than the IPM growth rate of 7.6%, while the rest grew equal to or slower. Regional Zone-Wise Performance1….
Growth Performance of Top 50 Companies in IPM (MAT Dec’24) The top 50 pharmaceutical companies in the Indian Pharmaceutical Market (IPM) have grown significantly in various zones (West, South, North, and East). The following key insights emerge:• The top 30 cities contributed 34% to IPM Sales for MAT Dec’24.• The…